Skip to content
Search

Latest Stories

Second pharma firm admit illegal role in agreement for lifesaving drug

Two of three companies under investigation have now admitted illegally taking part in an agreement that resulted in significant price hikes for an essential medicine, the Competition and Markets Authority (CMA) revealed.

Tiofarma has admitted that it took part in an agreement that contributed to the price of fludrocortisone acetate tablets supplied to the NHS increasing by up to 1800 per cent.


The regulator, in October 2019, provisionally found that Aspen, Tiofarma and Amilco had broken the law.

Aspen had already admitted its part in the agreement which may result in a £2.1 million fine while Tiofarma now agreed to pay a maximum fine of £186,000 if there is a formal final decision that the law has been broken.

The agreement involved Tiofarma and Amilco staying out of the UK fludrocortisone market so that Aspen could maintain its position as the sole UK supplier.

In exchange, Tiofarma was given the right to be the sole manufacturer of the drug for direct sale in the UK, and Amilco received a 30 per cent of the increased prices that Aspen was able to charge, according to CMA provisional findings.

However, Amilco has not made the admission of liability so far. CMA said its probe is ongoing.

More For You

First daily pill for endometriosis to be available on NHS

Instead of travelling to clinics for injections, endometriosis patients can take a daily tablet at home

Getty Images

New endometriosis pill approved for NHS use, but only few patients will benefit

The National Institute for Health and Care Excellence (NICE) has approved a new pill for the treatment of endometriosis, providing hope for thousands of women affected by the debilitating condition.

The pill, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), is the first long-term daily pill approved for use in the UK to treat endometriosis, and it is expected to help about 1,000 patients every year.

Keep ReadingShow less
​RPS urges its members and fellows to vote in favour of Royal College for “a stronger, louder voice”

The Special Resolution Vote will remain open until 5 p.m. on Thursday, 24 March 2025.

Getty Images

Royal College voting begins: A historic moment in the profession’s evolution

Becoming a royal college will ensure pharmacy profession gains the recognition and authority it deserves, says RPS president Professor Claire Anderson.

Starting today (13), members and fellows of the Royal Pharmaceutical Society (RPS) will begin voting on the proposed changes to its Royal Charter, marking the beginning of a historic shift toward becoming the Royal College of Pharmacy.

Keep ReadingShow less
GPs to play crucial role in transforming Wales’ health service

Jeremy Miles

(Photo credit: www.gov.wales )

Strengthening GPs’ role key to transforming healthcare - Jeremy Miles

Welsh health secretary Jeremy Miles has recognised the need to transform health services and bring healthcare closer to home.

Speaking at the recent Welsh Local Medical Committees Conference, he emphasised that strengthening the role of GPs would be crucial in improving patient healthcare and tackling NHS waiting lists.

Keep ReadingShow less
NPA and IPA urge NHS England to release pharmacy economic analysis immediately

Pharmacy bodies call for transparency on the funding gap amid ongoing contract negotiations.

Getty Images

Pharmacy bodies demand immediate release of economic analysis

The National Pharmacy Association (NPA) and the Independent Pharmacies Association (IPA) have jointly written to NHS England, demanding the immediate release of the independent economic analysis of pharmacy finances commissioned last autumn.

An open letter, signed by the owners of 3,034 pharmacies in England, calls for transparency on the funding gap amid ongoing contract negotiations.

Keep ReadingShow less